A well planned managed care strategy is crucial for a successful launch and brand plan
The commercial success of new pharma products is heavily reliant on a smart payer strategy that takes multiple variables into account, from understanding different key payer stakeholders to developing strategies that effectively communicate a product’s value and align on its positioning. In today’s pharmaceutical environment, a generalized, one-size-fits-all approach isn’t sufficient for optimizing a product’s revenue or patients’ access to it.
Instead, manufacturers need a detailed strategy that integrates with their overall brand strategy. This is our focus at Two Labs Market Access.
To maximize your revenue, it’s vital that you develop proper modeling that takes payers, physicians and patients into consideration.
Gaining a thorough understanding of the market, as well as future projections, is critical for sound decision making.
To understand the pricing and market access potential for new treatments, clients need to hear from KOLs and government policy makers.
In today’s competitive landscape, a one-size-fits-all approach to your market access strategy is not enough.
The right payer strategy takes a holistic approach, one that considers the unique business objectives of various payers to develop strategies that seek to maximize script volume and profitability.
Just as with launching a new product, managing a product’s loss of exclusivity (LOE) requires strategic planning and oversight. Generally, we help clients in three primary ways when managing LOE projects.
It’s imperative manufacturers have a thorough understanding of out of pocket (OOP) costs and the reimbursement support options available to them.
No matter where you are in the process, we’re here to support, advise, and implement key strategies to ensure the success of your product.
110 Riverbend Avenue, Suite 100
Powell, OH 43065
Phone: (614) 389-4004
Fax: (866) 259-4324
Email: info@twolabs.com
© Copyright 2023 | Powered by PRISM
How we maximized value and simplified access for an emerging biotech company’s new drug.